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Abstract: The ﬁ  rst in class proteasome inhibitor bortezomib (B) received its initial regulatory 
approval for therapy of patients with multiple myeloma (MM) in the relapsed/refractory setting. 
Modulation of proteasome function, however, is also a rational strategy for chemosensitiza-
tion, and a variety of agents have shown synergistic activity with bortezomib pre-clinically, 
including anthracyclines. This formed the basis for evaluation of a regimen of bortezomib with 
pegylated liposomal doxorubicin (PLD). PLD+B, in a phase I study, induced a predictable and 
manageable toxicity proﬁ  le, and showed encouraging anti-MM activity. In a recent interna-
tional, randomized phase III trial, PLD+B demonstrated a superior overall response rate and 
response quality compared to bortezomib alone, as well as a longer time to progression, duration 
of response, progression-free survival, and overall survival. Sub-analyses revealed beneﬁ  ts in 
almost all clinically relevant subgroups, including several which would be considered to have 
high-risk disease. These ﬁ  ndings have led to the establishment of the PLD+B regimen as one 
of the standards of care for patients with relapsed and/or refractory myeloma. Efforts are now 
underway to build on this combination further by adding other active anti-myeloma agents. 
In this review, we will discuss the role of PLD+B as an important addition to our therapeutic 
armamentarium for patients with MM.
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Introduction to management strategies 
incorporating bortezomib and anthracyclines 
in multiple myeloma
In May 2003, bortezomib (B) (Velcade®; Millenium Pharmaceuticals), a ﬁ  rst in class 
proteasome inhibitor, received accelerated approval by the Food and Drug Administra-
tion (FDA) for use in patients with multiple myeloma (MM) who had received at least 
2 prior lines of therapy, and had progressive disease on the most recent therapy.1 In 
March 2005, this approval was amended to allow the use of bortezomib for patients 
with MM after 1 or more prior lines of therapy.2 In the relapsed or primary refractory 
setting, single-agent bortezomib has provided response rates of 27% to 43%, with 
median times to progression of 6.2 to 7.0 months.3–5 To improve these outcomes, 
combinations of bortezomib with other agents active in MM have been explored. 
Among these drug classes are anthracyclines, whose efﬁ  cacy in treating myeloma 
was established with the combination of vincristine-doxorubicin-dexamethasone 
in the 1980s.6–11 Pre-clinical studies combining bortezomib and doxorubicin have 
demonstrated the ability of each drug to reduce chemoresistance to the other, and 
indeed these drugs have shown synergy in combination.Therapeutics and Clinical Risk Management 2009:5 152
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Unfortunately, the administration of continuous infusion 
doxorubicin is complicated by the requirement for central line 
placement which increases the risks of infections and throm-
bosis, while doxorubicin itself is associated with the risks 
of neutropenia and cardiotoxicity. In an effort to maintain 
the efﬁ  cacy of doxorubicin, while improving its tolerability, 
a pegylated, liposomal form of doxorubicin (PLD, Doxil®; 
Johnson and Johnson) was developed. With a half-life of 
approximately 79 hours, a single 60- to 90-minute adminis-
tration of pegylated liposomal doxorubicin is comparable in 
efﬁ  cacy to continuous infusion doxorubicin, but has a lower 
incidence of neutropenia, alopecia and cardiac toxicity.12,13
The pre-clinical synergy observed between proteasome 
inhibitors and anthracyclines led to the development of 
clinical trials investigating the use of these drug classes in 
combination. In this review, we discuss treatment strategies 
using bortezomib together with PLD in patients with relapsed 
and refractory MM.
Mechanism of action
Doxorubicin
Doxorubicin, an anti-tumor anthracycline antibiotic produced 
by the soil fungus Streptomyces peucetius, has been used in 
a number of malignancies including MM. Its cytotoxicity is 
thought to result in large part from inhibition of the DNA 
repair enzyme, topoisomerase II.14,15 It also intercalates into 
double-stranded DNA, producing structural changes that 
interfere with DNA and RNA synthesis.16–18 Doxorubicin 
and other anthracyclines also chelate iron, thereby generat-
ing reactive oxygen species, such as oxygen free radicals, 
hydroxyl radicals, and hydrogen peroxide, that cleave DNA, 
messenger mRNA, proteins, and lipids. The formation of 
oxygen free radicals and the peroxidation of lipids also 
contribute to the cardiac toxicity that is characteristic of 
non-liposomal anthracyclines.19,20
Bortezomib
Bortezomib is a dipeptide boronic acid analog which targets 
the ubiquitin-proteasome pathway (UPP) by inhibiting the 
function of the 26S proteasome complex. Inhibition of the 
UPP blocks protein and transcription factor degradation, 
leading to accumulation of misfolded/damaged proteins, 
and inducing heat shock stress responses within the cell.21,22 
Bortezomib mediates its cytotoxic effects via alterations 
in multiple pathways including inhibition of nuclear factor 
kappa-B (NF-κB) signaling. In the quiescent cell, NF-κB 
is bound to the inhibitory protein IκB, rendering it inac-
tive. However, with phosphorylation, ubiquitination, and 
degradation of IκB by the ubiquitin-proteasome pathway, 
NF-κB is released from the bound state and translocates from 
the cytoplasm to the nucleus. Activated NF-κB initiates an 
immune/inﬂ  ammatory response via increased gene transcrip-
tion of multiple cytokines, and also contributes to cellular 
resistance to apoptosis and chemotherapy resistance. Bort-
ezomib inhibits IκB degradation, thereby suppressing NF-κB 
activity and contributing to apoptosis.21,23–26 Bortezomib’s 
anti-tumor activity is also mediated by a number of pro-
apoptotic pathways including accumulation of p53, p21 and 
p27, activation of c-Jun N-terminal kinase (JNK), inhibition 
of the interleukin (IL)-6-induced Ras/Raf/mitogen-activated 
protein kinase (MAPK) pathway, and interference with the 
anti-apoptotic effects of Bcl-2.26–32 Additionally, preclinical 
studies with bortezomib have demonstrated a reduction in 
levels of cytokines (IL-6), angiogenesis factors (vascular 
endothelial growth factor), and growth factors (insulin-like 
growth factor-1), which among other effects inhibits adhesion 
of myeloma cells to bone marrow stromal cells.23,25,26,28
Rationale for combination
One of the mechanisms of doxorubicin resistance is via 
up-regulation of NF-κB expression.31,32 As bortezomib sup-
presses the activity of NF-κB, chemo-resistance to PLD 
induced by this mechanism would be abrogated by using 
these drugs in combination.29 Bortezomib may also sensi-
tize myeloma cells to DNA damage by down-regulating 
the transcription of DNA repair enzymes, as demonstrated 
in in vitro studies as well as by gene expression proﬁ  ling.30 
P-glycoprotein, encoded in the multi-drug resistance gene 
1 (MDR1), functions as a cell membrane transporter respon-
sible for the efﬂ  ux of toxins including multiple chemotherapy 
agents.6,27 Preliminary data suggest proteasome inhibition 
decreases expression of P-glycoprotein, and subsequently 
bypasses a well-deﬁ  ned mechanism of multi-drug resis-
tance.33 Cell adhesion mediated drug resistance (CAM-DR) 
also contributes to the development of resistance to conven-
tional chemotherapeutics, and in addition to suppression of 
NF-κB activity, bortezomib may overcome CAM-DR.30
Anthracyclines, in turn, may also overcome bortezomib 
resistance by inhibiting the mitogen-activated protein kinase 
phosphatase (MPK-1) pathway. One of several mechanisms 
of proteasome inhibitor-induced apoptosis is via activation 
of JNK. However, bortezomib induces MPK-1, which can 
dephosphorylate and inactivate JNK. Anthracyclines have 
been shown to inhibit MPK-1 activity, potentially contribut-
ing to the synergy of doxorubicin and bortezomib.34 Combi-
nation studies of bortezomib and anthracyclines in in vitro Therapeutics and Clinical Risk Management 2009:5 153
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and in vivo models have demonstrated improved inhibition 
of MPK-1, increased activation of JNK, and increased 
apoptosis. These preclinical observations led investigators 
to develop clinical trials evaluating the combination of 
bortezomib and PLD.30
Pharmacology/pharmacokinetics
In a phase I study of PLD+bortezomib (PLD+B), the 
pharmacodynamics of bortezomib were evaluated using an 
ex vivo assay of 20S-proteasome inhibition by measuring 
the chymotryptic proteasome protease activity.35 Proteasome 
inhibition on Days 1 and 4 prior to PLD administration was 
63.7%, and with the addition of PLD on days 8 and 11, 
mean proteasome inhibition increased to 67.4%. As might 
be expected, proteasome inhibition was lowest at the starting 
bortezomib dose of 0.9 mg/m2, with no difference noted 
between the 1.05 and 1.50 mg/m2 dose levels.
The t1/2 of PLD was 80 hours and remained constant 
across escalating bortezomib dose cohorts; suggesting no 
signiﬁ  cant alteration in the pharmacokinetic and pharma-
codynamic proﬁ  le of bortezomib and PLD when combining 
the two agents.35
Efﬁ  cacy studies
The combination of bortezomib and pegylated liposomal 
doxorubicin was ﬁ  rst evaluated clinically in a phase 1 study 
led by Orlowski et al with 42 patients having any conﬁ  rmed 
hematologic malignancy. Notably, the majority (n = 24) had 
MM.35 Dose reductions and treatment delays were frequent 
at the 1.5 and 1.6 mg/m2 dose levels of bortezomib, and 
therefore 1.3 mg/m2 of bortezomib on days 1, 4, 8, and 11 
in combination with 30 mg/m2 of PLD on day 4 of a 21-day 
cycle was established as the optimal dosing regimen. Among 
22 evaluable patients with MM, 36% achieved either com-
plete remission (CR) or near CR, and another 36% achieved 
partial remission (PR). Prior to study enrollment, 13 patients 
had received anthracyclines to which their disease had either 
not responded, or initially responded but then derived no 
further beneﬁ  t; among them, 38% achieved CR or near CR, 
and another 23% achieved PR. With extended follow-up, 
the median time to disease progression (TTP) among the 
22 evaluable patients was 9.3 months, with a median time 
to re-treatment (TTRT) of 24.2 months, and median overall 
survival of 38.3 months. Both the median TTP and median 
TTRT compared favorably to outcomes seen on the patients’ 
prior therapy.35,36 This experience led to a prospective, 
international, randomized, controlled phase III trial led by 
Orlowski et al comparing single-agent bortezomib with the 
combination of PLD+B in patients with relapsed or primary 
refractory MM.37 The results of this trial led the FDA to 
approve combination therapy with PLD+B in May 2007, 
for the treatment of bortezomib-naïve patients who had pro-
gressed after at least 1 prior line of therapy.38 In this study, 
646 patients, who had progressed after  1 line of therapy 
and were bortezomib-naïve, were enrolled and stratiﬁ  ed 
according to β2-microglobulin and response to prior therapy 
(relapsed vs refractory). Patients on both arms were treated 
with 1.3 mg/m2 of bortezomib on days 1, 4, 8 and 11 on a 
21 day cycle, while patients on the combination arm also 
received 30 mg/m2 of PLD on day 4 of each cycle. Patients 
were treated for up to 8 cycles or until complete response, 
disease progression, or unacceptable toxicity developed, 
though patients tolerating therapy were allowed to continue 
beyond 8 cycles if they showed continued disease response. 
The primary endpoint was TTP on an intent-to-treat popula-
tion, while secondary endpoints were overall survival (OS), 
overall response rate (complete response + partial response) 
as deﬁ  ned by the European Blood and Marrow Transplant 
Group criteria, and safety proﬁ  le.39
Among patients treated with the combination of PLD+B, 
TTP was higher at 9.3 months, compared with 6.5 months 
among patients treated with bortezomib alone (p = 0.000004). 
Progression-free survival (PFS) was also longer in those 
treated on the combination arm than in those treated with 
bortezomib monotherapy (9.0 vs 6.5 months, p = 0.000026). 
An increase in the duration of response (DOR) from 7.0 
to 10.2 months with combination therapy paralleled the 
improvements seen in TTP and PFS. Early follow-up of 
survival data also suggested an improvement in 15-month 
OS among those treated with PLD+B compared with those 
treated with bortezomib alone (76% vs 65%, p = 0.03). By 
intent-to-treat analysis, the overall response rate (ORR) 
was similar between monotherapy (41%) and combination 
therapy arms (44%) (p = 0.43); however, rates of CR + very 
good partial response (VGPR) were higher (19% vs 27%) 
with combination therapy (p = 0.0157). When only response-
evaluable patients were included in the analysis, the overall 
response rate for bortezomib alone (n = 310) was 44% and 
that for PLD+B (n = 303) was 52% (p = 0.05).37
Braccalenti et al have taken an alternative approach to 
evaluating the effect of adding PLD to the anti-tumor activ-
ity of B. In an ongoing study, 40 mg/m2 of PLD given once 
every 21 days is added to bortezomib 1.3 mg/m2 (on days 
1, 4, 8, 11 for the ﬁ  rst 8 cycles, and then on days 1, 8, 15, 
and 22) after either 8 cycles (cohort 1) or 3 cycles (cohort 
2) of therapy. Among 5 patients enrolled in cohort 1, 4 had Therapeutics and Clinical Risk Management 2009:5 154
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objective responses with bortezomib and 1 had disease 
stabilization; the addition of PLD did not improve the 
quality of the responses achieved with bortezomib alone. In 
cohort 2, 9 of 17 evaluable patients had objective responses 
(52.9%) after 3 cycles of bortezomib monotherapy. Of these, 
7 patients had conversion of their remission from either PR 
(4 patients) or near CR (3 patients) to CR. Though we await 
further follow-up of this study, its preliminary results provide 
further evidence that adding PLD to bortezomib enhances 
activity of the latter in certain patients.40
Sub-group analyses from 
randomized phase III trial
A number of formal subgroup analyses were performed 
to compare the efﬁ  cacy of PLD+B with bortezomib alone 
among elderly patients, those with high-risk disease, those 
having prior autologous stem cell transplant (ASCT) and 
early relapse after ASCT, those with previous anthracy-
cline and thalidomide exposure, and those having one or 
multiple prior lines of therapy (Table 1). As described 
below, these subgroups all beneﬁ  ted from combination 
therapy. Subgroups that did not beneﬁ  t from combination 
therapy were those with low β2-microglobulin and those 
with chromosome 13 deletion.
In a pre-speciﬁ  ed subgroup analysis of 250 patients  65 
years of age, the addition of PLD improved TTP from 205 
days to 276 days (p = 0.0056, HR = 1.82, 1.18–2.79) and 
also improved DOR from 227 days to 311 days. ORR was 
also increased from 39% to 49% by combination therapy. 
The beneﬁ  t of adding PLD in this older patient population 
was comparable to that seen in younger patients.41
A second pre-speciﬁ  ed subgroup analysis evaluated 
the effect of adding PLD to bortezomib in patients with 
high-risk disease, where high-risk disease was deﬁ  ned as 
having either an elevated β2-microglobulin ( 5.5 mg/L) or 
primary refractory disease. TTP was signiﬁ  cantly increased 
in the combination therapy arm, both among patients 
having an elevated β2-microglobulin (178 vs 276 days; 
p = 0.0007), as well as among those having primary 
refractory disease (189 days vs median not reached, 
p = 0.0322). Patients with an elevated β2-microglobulin 
also showed improvement in ORR (33% vs 49%), and 
DOR (211 vs 310 days).42
The third pre-speciﬁ  ed subgroup analysis compared 
patients with and without a history of prior ASCT. In 
patients without a prior history of ASCT, TTP increased 
from 197 to 331 days (p = 0.0009) with the addition 
of PLD, ORR improved from 39% to 45%, and DOR 
increased from 204 days to 394 days. Similar beneﬁ  ts in 
TTP (197 vs 276 days, p = 0.0011) and DOR (227 days 
vs 309 days) were also observed in patients who had had 
a prior ASCT.43
Table 1 Subgroup analyses from phase III trial of bortezomib vs pegylated liposomal doxorubicin + bortezomib (PLD+B)
Subgroup ORR (%) TTP (days) p value
B PLD+B B PLD+B
Age   65 yrs 39 49 205 276 0.0056
ß2-microglobulin  5.5mg/L 33 49 178 276 0.0007
Primary refractory disease 48 43 189 MNR 0.0322
No prior ASCT 39 45 197 331 0.0009
Prior ASCT 46 50 197 276 0.0011
 2 prior lines of therapy N/A 186 276  0.0001
1 prior line of therapy N/A 199 330 0.036
Anthracycline naïve N/A 197 282 0.015
Anthracycline exposed N/A 197 295 0.0001
ISS stage 3 N/A 177 276  0.0007
ISS stage 2 N/A 186 250  0.004
ISS stage 1 N/A 223 331 0.067
TSD  2 years N/A 197 295  0.0001
TSD  2 years N/A 197 243 0.0033
Relapse  12 months post 
ASCT
74 93 
(p = 0.01)
205 276 0.13
Abbreviations: ASCT, autologous stem cell transplant; ISS, International Staging System; MNR, median not reached; N/A, not available; TSD, time since diagnosis; TPP, time 
to disease progression; ORR, overall response rate.Therapeutics and Clinical Risk Management 2009:5 155
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Bladé et al also presented a pre-speciﬁ  ed analysis to 
assess the efﬁ  cacy of combination therapy with PLD+B 
based on the number of prior lines of therapy and previous 
anthracycline exposure. The TTP was similar with PLD+B 
between those who had   2 lines of prior therapy (276 days) 
vs 1 prior therapy (330 days) (heterogeneity test, p = 0.523), 
as well as between those who were anthracycline-exposed 
(median 144 mg/m2 in both treatment arms) or -naïve 
(heterogeneity test, p = 0.716). The incidence of symptomatic 
cardiac events was also comparable between treatment arms 
in each subgroup. There was a uniform beneﬁ  t with PLD+B 
combination therapy in TTP regardless of the number of prior 
lines of therapy and anthracycline exposure.44
The impact of treatment with prior thalidomide on out-
comes of patients treated with PLD+B was also evaluated in 
a post hoc analysis of the phase III study by Sonneveld et al. 
Prior exposure to thalidomide did not affect TTP (295 days 
for thalidomide-naïve vs 270 days for thalidomide-exposed) 
or DOR (310 days for thalidomide-naïve vs 319 days for 
thalidomide-exposed). ORR was also comparable between 
the thalidomide-naïve and -exposed arms (48% vs 47%).45 
A second post hoc analysis by Sutherland et al evaluated the 
effect of International Staging System (ISS) disease stage and 
time since initial diagnosis (TSD; 2 cohorts:  2 years and  2 
years) on outcomes of patients treated with PLD+B. There 
was a consistent beneﬁ  t in TTP across ISS stages 2 (HR = 1.8, 
p   0.004) and 3 (HR = 2.1, p   0.007) but not ISS stage 1 
(HR = 1.6, p = 0.067). TSD did not affect the beneﬁ  t in TTP 
( 2 years, HR 1.83;  2 years, HR = 1.75).46
A post hoc analysis of outcomes of patients, who 
had an early relapse ( 12 months) after ASCT, was 
also performed (Kumar et al). Among these patients, the 
12-month post-randomization survival was signiﬁ  cantly 
higher in those treated with combination therapy (93% vs 
74%, p = 0.01). TTP in the early relapse cohort also sug-
gested improvement with combination therapy (205 vs 276 
days), but did not reach statistical signiﬁ  cance (p = 0.13, HR 
= 0.94). A similar beneﬁ  t in TTP was noted among patients 
whose myeloma relapsed 12 months or later after ASCT, 
suggesting that the beneﬁ  ts of treatment with combination 
therapy were not affected by timing of relapse after ASCT. 
No differences in ORR (CR+PR) or VGPR rates were seen 
in patients with early vs late relapses, or between treatment 
arms within each group.47
Safety/tolerability
Based on the risk of dose reductions and delays at higher 
dose levels of bortezomib (PLD was maintained at a ﬁ  xed 
dose level) during the phase I study of PLD+B, a dosing 
schedule of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11, and 
PLD 30 mg/m2 on day 4 on a 21-day cycle was determined 
to be the most feasible for multiple cycle administration.35 
Neutropenia and thrombocytopenia were the most common 
reasons for therapy-related dose delays, followed by diarrhea 
and fatigue.35
In the phase I study, 43% of patients experienced  grade 3 
thrombocytopenia, and 40% and 17% respectively experienced 
 grade 3 lymphopenia and neutropenia. The most notable 
infectious complications were febrile neutropenia (10%) 
and pneumonia (14%).35 By comparison, 23% of patients 
in the PLD+B arm of the phase III study developed 
 grade 3 thrombocytopenia and 29% had  grade 3 
neutropenia (Table 2). Though the incidence of  grade 3 
neutropenia was nearly twice that seen among those treated 
with bortezomib alone (15%), the incidence of febrile 
neutropenia was comparable between study arms (2% vs 3%). 
Rates of thrombocytopenia were also similar.37
Peripheral neuropathy (PN) is one of the most common 
toxicities of single-agent bortezomib, with an incidence of 
grade 1–4 events seen in 36% of patients and grade 3–4 events 
in 8% in the APEX trial.4 In the phase I study of PLD+B, 
where doses of bortezomib up to 1.5 mg/m2 were evalu-
ated, an incidence of 55% (12% grade 3–4) was observed.35 
However, in the phase III study of bortezomib vs PLD+B, 
where 1.3 mg/m2 of bortezomib was given to all patients, rates 
of peripheral neuropathy were comparable to those seen in 
previous clinical trials of single-agent bortezomib.37 Rates 
of peripheral neuropathy were also comparable between 
treatment arms of this study (PN grades 1–4: 39% and 35% 
respectively;  grade 3: 9% and 4%), despite an equivalent 
number of median cycles of therapy (n = 5) and similar 
cumulative dose of bortezomib (monotherapy, 24.4 mg/m2; 
combination, 23.2 mg/m2). This suggests that PLD added no 
further neurotoxicity to bortezomib.37
Reducing the potential for cardiac toxicities with 
doxorubicin was one of the most important reasons for 
the development of PLD. Data from the phase III study of 
bortezomib vs PLD+B showed that 7% and 9% of patients 
respectively had a fall in their left ventricular ejection frac-
tion by  15%, suggesting that PLD does not add signiﬁ  cant 
risk of cardiotoxicity to bortezomib. Congestive heart failure 
was seen in 3% of patients on each treatment arm.37 In addi-
tion, in a pre-speciﬁ  ed analysis by Bladé et al evaluating the 
role of prior anthracycline exposure, there was no increase 
in the incidence of symptomatic cardiac events with prior 
anthracycline exposure.44Therapeutics and Clinical Risk Management 2009:5 156
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In the phase III study, the addition of PLD to bortezomib 
resulted in a statistically signiﬁ  cant increase in the incidence 
of nausea, vomiting, and diarrhea.37 Diarrhea (10%), bowel 
obstruction (7%), and lower gastrointestinal bleeding (5%) 
were also seen in the phase I study of PLD+B.35 Finally, 
palmar plantar erythrodysesthesia, now known as hand-foot 
syndrome, was noted in 21% of patients (all grade 1–2) in the 
phase I study and 16% of patients in the phase III study.35,37 
It required discontinuation of PLD in 5% of patients on the 
latter study.
In subset analyses of the phase III study, the effect of 
age, prior stem cell transplant, and high-risk disease on the 
incidence of adverse events was evaluated.41–43 With the 
exception of an increased incidence of grade  3 neutrope-
nia among patients  65 years old, age did not impact the 
development of adverse events with combination therapy. 
Similarly, having primary refractory myeloma, a history of 
prior ASCT, or a serum β2-microglobulin  5.5 mg/L, did 
not affect rates or severity of adverse events encountered 
with PLD+B.42,43
PLD+B-based combinations in 
relapsed/refractory disease (Table 3)
Given the established activity of dexamethasone in combina-
tion with bortezomib as well as anthracyclines, Jakubowiak 
et al evaluated the addition of 40 mg of dexamethasone on 
days 1–4 to PLD+B in the relapsed/refractory setting.48 In this 
study, patients were treated on a 21-day cycle of therapy 
for up to 6 cycles. Among 18 evaluable patients, who had 
received a mean of 3.6 prior regimens, the ORR was 55%, and 
33% achieved CR/nCR. Grade 3/4 neutropenia and thrombo-
cytopenia were each seen in 7 patients; pneumonitis was seen 
in 5 patients and, unfortunately, resulted in 1 death.48
The combination of thalidomide-PLD-dexamethasone 
(ThaDD) has also provided noteworthy results, with an 
ORR of 75.5%, and CR rate of 30% in the relapsed/refrac-
tory setting.49 Building on this regimen, Ofﬁ  dani et al 
sought to improve these response rates further by adding 
bortezomib (ThaDD-V). In the induction phase of this 
feasibility study, patients received 100 mg of thalidomide 
daily with PLD 30 mg/m2 iv on day 4, dexamethasone 
20 mg on days 1 to 2, 4 to 5, 8 to 9, 15 to 16, and bortezo-
mib 1.3 mg/m2 on days 1, 4, 8, and 11 of every 28 days. 
Patients then alternated taking bortezomib 1 mg/m2 iv 
days 1, 8, 15 with dexamethasone 20 mg on days 1 to 2, 
8 to 9, 15 to 16, and thalidomide 100 mg daily with dexa-
methasone 40 mg on days 1 to 4, every other cycle for a 
total 6 cycles, as consolidation therapy. Finally, patients 
received thalidomide 100 mg daily as a maintenance regi-
men until disease relapse. The ORR seen in 20 evaluable 
patients was 80%, of which 40% achieved either CR or 
stringent CR.50 However, as 9 of the 20 patients developed 
grade 2–3 peripheral neuropathy, the authors subsequently 
amended their protocol to reduce the dose intensity of both 
bortezomib and thalidomide.50,51
Chanan-Khan et al have also evaluated the combina-
tion of thalidomide, B, and PLD, but with a steroid-sparing 
approach. In this phase II study, patients were given 1.3 mg/m2 
of bortezomib on days 1, 4, 15, and 18 together with 20 mg/m2 
PLD on days 1 and 15; 200 mg thalidomide was given daily 
with low-dose warfarin prophylaxis. Among 17 evaluable 
patients, the ORR was 65%, and CR rate was 23%; PFS 
was 10.9 months. Among this heavily pre-treated popula-
tion, responses were seen regardless of the prior therapies 
that patients had received. Grade 2 palmar plantar erythro-
dysesthesia developed in 2 patients, and 1 patient had grade 
3 cellulitis. Importantly, no thromboembolic events were 
noted with this combination; and no patients developed 
evidence of cardiotoxicity, regardless of exposure to prior 
anthracyclines.52
Table 2 Grade 3–4 adverse events in phase III trial of bortezomib vs pegylated liposomal doxorubicin + bortezomib (PLD+B)
Adverse event Bortezomib (%) N = 318 PLD+B (%) N = 318 p value
All drug-related adverse events 165 (52) 217 (68)  0.001
Thrombocytopenia 49 (16) 71 (23) 0.249
Neutropenia 46 (15) 94 (29)  0.001
Febrile neutropenia 2 (2) 3 (3) n/a
Peripheral neuropathy 39 (9) 35 (4) n/a
Cardiotoxicity 7 (3) 10 (2) n/a
Thromboembolic events 1 (1) 1 (1) n/a
Diarrhea 14 (4) 22 (7) 0.034
Palmar plantar erythrodysesthesia 0 (0) 15 (5)  0.001Therapeutics and Clinical Risk Management 2009:5 157
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Presently, Chari et al are evaluating the addition of 
melphalan to PLD+B in a phase I/II dose escalation trial.53 
Based on preliminary data from this study, 4 evaluable 
patients have been enrolled and treated at the ﬁ  rst dose level, 
on which they have received PLD 10 mg/m2 and melphalan 
5 mg/m2 on day 1, and bortezomib 0.7 mg/m2 on days 1, 4, 
8 and 11, on a 28-day cycle. A maximum of 6 cycles are 
planned. At the time of publication, 1 patient had achieved 
nCR and 2 patients had stable disease. No DLTs were 
reported, though 1 patient had transient grade 3 neutropenia.53 
Further updates of this study are necessary before conclusions 
may be drawn about this regimen.
Conclusions
The management of MM has changed rapidly over the past 
10 years with increased understanding of the biology of the 
ubiquitin proteasome pathway, mechanisms of chemoresis-
tance to this pathway, and methods of targeting it for treat-
ment. Combination therapy with PLD+B is an important 
therapeutic option for patients with relapsed or refractory 
myeloma that provides superior outcomes to single-agent 
bortezomib, including improved 15-month OS rates. As 
patients with relapsed or refractory MM have often previously 
received anthracyclines, thalidomide, and/or autologous stem 
cell transplant, it is signiﬁ  cant that PLD+B improves patient 
outcomes irrespective of these prior exposures. The lack of 
further beneﬁ  t seen with adding PLD to bortezomib in patients 
with low β2-microglobulin and deletion of chromosome 13 
suggest that bortezomib may be solely responsible for the 
responses seen in these subgroups of patients.
The tolerability profile of PLD+B is noteworthy. 
Treatment emergent peripheral neuropathy is a common 
clinical challenge in patients with MM. That PLD is able to 
improve patient outcomes without exacerbating symptoms 
of neuropathy adds to its usefulness. This steroid-sparing 
combination is also a valuable choice for patients with poorly 
controlled diabetes mellitus and those who are otherwise 
steroid intolerant. It is equally important that in a disease 
with a median age at diagnosis of 70 years, this combination 
does not increase the risk of cardiotoxicity compared with 
bortezomib alone.54 Finally, the lack of need for prophylactic 
anticoagulation, which is in contrast to immunomodulatory 
derivative (Imid®)-steroid combinations, is advantageous 
for patients at risk for falls, or with other bleeding tenden-
cies. While these advantages are important, clinicians must 
be vigilant for the gastrointestinal toxicities, neutropenia, 
stomatitis, and hand-foot-syndrome that can be seen with 
PLD+B, so that these may be promptly addressed if they 
develop.
Ongoing phase II studies are currently evaluating the 
combination of PLD+B with such agents as dexamethasone, 
thalidomide, and melphalan in the relapsed/refractory setting. 
These trials have a limited number of patients and follow-up 
to date; however mature data may suggest additional treat-
ment options in the future.
Because of its signiﬁ  cant activity in the relapsed/
refractory setting, with manageable and non-overlapping 
toxicities, PLD+B is also being evaluated as induction 
therapy prior to ASCT. This Cancer and Leukemia Group B 
(CALBG) study led by Orlowski et al enrolled 63 patients 
with symptomatic MM requiring therapy on the same 
B-PLD schema utilized in the phase 3 study. Preliminary 
response data on 29/63 patients demonstrated a CR/nCr rate 
of 28% and ORR of 79%. Stem cell collection, in a limited 
Table 3 Pegylated liposomal doxorubicin + bortezomib combinations in relapsed/refractory setting
Author Phase 
of study
Regimen Dose Evaluable 
pts (#)
PR (%) CR/nCR (%) PFS/TTP 
(med. months)
Orlowski22 I B-PLD B 0.9–1.5 mg/m2 d 1, 4, 8, 11 
PLD 30 mg/m2 d 4
22 36 36 9.3 (TTP)
Orlowski22 III B vs B-PLD B 1.3 mg/m2 d 1, 4, 8, 11 ± PLD 
30 mg/m2 d 4
646 41 vs 44 
(ORR)
10 vs 13 6.5 vs 9.3 (TTP) 
6.5 vs 9.0 (PFS)
Chanan-Khan52 II B-PLD + T B 1.3 mg/m2 d 1, 4, 15, 18 PLD 
20 mg/m2 d 1, 15 T 200 mg daily
17 42 23 (all CR) 10.9 (PFS)
Jakubowiak48 II B-PLD + D B 1.3 mg/m2 d 1, 4, 8, 11 PLD 
30 mg/m2 d 4 D 40 mg d 1–4
18 22 33 N/A
Chari53 I/II B-PLD + M B 0.7–1.0 mg/m2 d 1, 4, 
8, 11 PLD 10–20 mg/m2 
d 1 M 5–10 mg/m2 d 1
4 0 25 N/A
Abbreviations: B, bortezomib; D, dexamethasone; M, melphalan; PLD, pegylated liposomal doxorubicin;   T, thalidomide; PR, partial response; CR, complete response; nCR, near 
complete response; ORR, overall response rate; PFS, progression-free survival;   TTP, time to disease progression.Therapeutics and Clinical Risk Management 2009:5 158
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number of evaluable patients, was not compromised.55 If 
longer follow-up conﬁ  rms these promising results, this 
steroid-sparing combination may provide an effective 
option for patients with improved tolerability over other 
currently used regimens.
In future clinical trials of PLD+B, it will be useful to 
assess whether ﬂ  uorescence in situ hybridization (FISH), 
conventional cytogenetics, and/or molecular proﬁ  ling can be 
used to determine which patients are most likely to beneﬁ  t 
from this regimen.
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